Hikma Pharmaceuticals (HIK) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition adds commercialized products, a pipeline of 10 ready-to-use injectable products, and complex manufacturing technologies, supporting growth and high margins in the injectables division.

• Provides a large, technologically advanced manufacturing facility in the US and an R&D center in Croatia, enhancing capacity and innovation.

• Strategic fit with focus on increasing capacity, R&D, and specialty products, aligning with long-term growth objectives and scaling US operations.

• Diversifies and enriches the US injectables portfolio, strengthening position in the US market and serving hospital and patient needs.

• CEO and Injectables President highlight the deal's value in scaling US operations.

Financial terms and conditions

• Cash consideration of $135 million, with up to $50 million in contingent payments tied to regulatory and commercial milestones.

• Acquisition brings $75 million in annualized revenue, initially with slightly lower margins than the existing injectables business but expected to improve as synergies are realized.

• Neutral to core earnings in the first 12 months post-closing, accretive thereafter.

• Includes milestone-based contingent payments tied to sales of a specific product.

Synergies and expected cost savings

• Significant expansion of manufacturing capacity, with the Cleveland facility expected to increase injectables output after a two- to three-year enhancement project.

• Anticipated margin improvement as manufacturing transitions in-house and products are integrated into existing facilities.

• Acquisition reduces planned capital expenditures by leveraging the new site for future investments.

• Enhanced contract manufacturing potential due to increased capacity and improved productivity through automation.